ArticleCancer research2021
Tumor-Infiltrating B Lymphocyte Profiling Identifies IgG-Biased, Clonally Expanded Prognostic Phenotypes in Triple-Negative Breast Cancer.
Open access · greenAbstract read
In one paragraph
Article in Cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers.
0numbers the graph read from it
0cells of the map it votes in
71citing papers in PubMed
5.1field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
71 citing papers in PubMed, 94 citations in OpenAlex.
- B cells and humoral immunity in melanoma: regulatory and autoimmune-like features and implications for immunotherapy.Oncoimmunology · 2026Review
- B Cells and Tumor Immunometabolism: Emerging Insights into Immune Regulation and Therapeutic Resistance.Antibodies (Basel, Switzerland) · 2026Review
- The multifaceted roles of tumor-infiltrating plasma cells in cancer immunology.Fundamental research · 2026Review
- Tumor-infiltrating B cells evolve towards interferon-rich trajectories aligned with immunotherapy in melanoma.Journal of experimental & clinical cancer research : CR · 2026Article
- Developing a Phosphodiesterase 10A Inhibitor as a Novel Therapeutic Agent for Triple-Negative Breast Cancer.Cells · 2026Article
- Analytical validity of CD20 as a biomarker in breast cancer patients using tissue microarrays and whole slide sections.Biomarkers in medicine · 2026Article
- KRT80 promotes colon adenocarcinoma progression via stat3 pathway activation and immune microenvironment remodeling.Translational cancer research · 2026Article
- Tumor-infiltrating B cells participate in shaping the immunosuppressive microenvironment in solid tumors.International journal of cancer · 2026Review
- Cancer neuroscience: signaling pathways and new therapeutic strategies for cancer.Signal transduction and targeted therapy · 2026Review
- DNA methylation estimates of immune cell abundance have prognostic potential in triple negative breast cancer.Clinical epigenetics · 2026Article
- The progress and perspective of nanomedicine in modulating the tumor immune microenvironment.Acta pharmaceutica Sinica. B · 2026Review
- B-cells in breast cancer: current insights and challenges.Frontiers in oncology · 2026Review
- Mast cell release of TNF-α indirectly contributes to recalling B cells in the colorectal cancer milieu through the CCL20/CCR6 axis.Frontiers in immunology · 2026Article
- Constructing a prognostic signature of tumor-associated B lymphocytes in hepatocellular carcinoma via machine learning integration.Scientific reports · 2025Article
- Article
- The impact of immune cells on the risk of breast cancer: a Mendelian randomization study.Discover oncology · 2025Article
- An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer.Cancer research · 2025Article
- Comprehensive analysis of the systemic immune landscape across breast cancer subtypes and disease stages.Immuno-oncology technology · 2025Article
- Utilizing cohort-level and individual networks to predict best response in patients with metastatic triple negative breast cancer.NPJ precision oncology · 2025Article
- Circulating immunoregulatory B cell and autoreactive antibody profiles predict lack of toxicity to anti-PD-1 checkpoint inhibitor treatment in advanced melanoma.Journal for immunotherapy of cancer · 2025Article
11 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors at 6 institutions in 2 countries.
Robert J Harris *St. John's Institute of Dermatology, School of Basic and Medical Biosciences, King's College London, London, United Kingdom.
Anthony Cheung *St. John's Institute of Dermatology, School of Basic and Medical Biosciences, King's College London, London, United Kingdom.ORCID 0000-0002-2988-2786
Joseph C F NgRandall Center for Cell and Molecular Biophysics, King's College London, London, United Kingdom.ORCID 0000-0002-3617-5211
Roman LaddachSt. John's Institute of Dermatology, School of Basic and Medical Biosciences, King's College London, London, United Kingdom.ORCID 0000-0002-0118-4548
Alicia M ChenowethSt. John's Institute of Dermatology, School of Basic and Medical Biosciences, King's College London, London, United Kingdom.
Silvia CrescioliSt. John's Institute of Dermatology, School of Basic and Medical Biosciences, King's College London, London, United Kingdom.ORCID 0000-0002-1909-5957
Matthew FittallSt. John's Institute of Dermatology, School of Basic and Medical Biosciences, King's College London, London, United Kingdom.
Diana Dominguez-RodriguezSt. John's Institute of Dermatology, School of Basic and Medical Biosciences, King's College London, London, United Kingdom.
James RobertsSt. John's Institute of Dermatology, School of Basic and Medical Biosciences, King's College London, London, United Kingdom.ORCID 0000-0002-5412-3677
Dina LeviBreast Cancer Now Research Unit, School of Cancer and Pharmaceutical Sciences, King's College London, Guy's Cancer Center, London, United Kingdom.
Fangfang LiuBreast Cancer Now Research Unit, School of Cancer and Pharmaceutical Sciences, King's College London, Guy's Cancer Center, London, United Kingdom.
Elena AlbertsSt. John's Institute of Dermatology, School of Basic and Medical Biosciences, King's College London, London, United Kingdom.
Jelmar QuistBreast Cancer Now Research Unit, School of Cancer and Pharmaceutical Sciences, King's College London, Guy's Cancer Center, London, United Kingdom.
Aida SantaolallaUnit of Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
Sarah E PinderSchool of Cancer and Pharmaceutical Sciences, King's College London, Comprehensive Cancer Center, Guy's Hospital, London, United Kingdom.
Cheryl GillettSchool of Cancer and Pharmaceutical Sciences, King's College London, Comprehensive Cancer Center, Guy's Hospital, London, United Kingdom.ORCID 0000-0003-3643-4057
Niklas HammarUnit of Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
Sheeba IrshadSchool of Cancer and Pharmaceutical Sciences, King's College London, Comprehensive Cancer Center, Guy's Hospital, London, United Kingdom.ORCID 0000-0002-4419-7162
Mieke Van HemelrijckUnit of Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
Deborah K Dunn-WaltersFaculty of Health and Medical Sciences, University of Surrey, Guildford, United Kingdom.
Franca FraternaliRandall Center for Cell and Molecular Biophysics, King's College London, London, United Kingdom.
James F SpicerSchool of Cancer and Pharmaceutical Sciences, King's College London, Comprehensive Cancer Center, Guy's Hospital, London, United Kingdom.ORCID 0000-0003-3732-8491
Katie E LacySt. John's Institute of Dermatology, School of Basic and Medical Biosciences, King's College London, London, United Kingdom.
Sophia TsokaDepartment of Informatics, Faculty of Natural and Mathematical Sciences, King's College London, London, United Kingdom.ORCID 0000-0001-8403-1282
Anita GrigoriadisBreast Cancer Now Research Unit, School of Cancer and Pharmaceutical Sciences, King's College London, Guy's Cancer Center, London, United Kingdom.ORCID 0000-0003-3434-201X
Andrew N J TuttBreast Cancer Now Research Unit, School of Cancer and Pharmaceutical Sciences, King's College London, Guy's Cancer Center, London, United Kingdom.ORCID 0000-0001-8715-2901
Sophia N KaragiannisSt. John's Institute of Dermatology, School of Basic and Medical Biosciences, King's College London, London, United Kingdom. sophia.karagiannis@kcl.ac.uk.ORCID 0000-0002-4100-7810
Guy's Hospital · GBKing's College London · GBBreast Cancer Now · GBMRC Laboratory for Molecular Cell Biology · GBKarolinska Institutet · SEUniversity of Surrey · GB
Funding
Biotechnology and Biological Sciences Research Council BB/H018409/1Breast Cancer Now BREAST CANCER NOW KCL RESEARCH UNITBritish Heart Foundation NH/12/2/29427Cancer Research UK 24869Cancer Research UK 28990Cancer Research UK A11060Cancer Research UK A11527Cancer Research UK A15774Cancer Research UK A22788Medical Research Council G0600097Medical Research Council MC_PC_19041Medical Research Council MR/L01257X/1Medical Research Council MR/L01257X/2Medical Research Council MR/L023091/1
Abstract
In breast cancer, humoral immune responses may contribute to clinical outcomes, especially in more immunogenic subtypes. Here, we investigated B lymphocyte subsets, immunoglobulin expression, and clonal features in breast tumors, focusing on aggressive triple-negative breast cancers (TNBC). In samples from patients with TNBC and healthy volunteers, circulating and tumor-infiltrating B lymphocytes (TIL-B) were evaluated. CD20
Indexed as
Antigens, CDAntigens, CD20Antigens, Differentiation, T-LymphocyteBase SequenceB-LymphocytesCD69 AntigensCell Line, TumorFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansImmunoglobulin DImmunoglobulin GImmunohistochemistryLectins, C-TypeLymphocytesAntigens, CDAntigens, CD20Antigens, Differentiation, T-LymphocyteCD69 AntigensImmunoglobulin DImmunoglobulin GLectins, C-TypeReceptors, Antigen, B-CellTumor Necrosis Factor-alphaTumor Necrosis Factor Receptor Superfamily, Member 7
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.